Lilly said Tuesday ahead of the market open that Talz, a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine, met the primary and all major secondary endpoints up to 12 weeks in the Phase 4 IXORA-R study.
Taltz has been approved for treating adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and also for adults with psoriatic arthritis.
The IXORA-R trial evaluated the efficacy and safety of Taltz versus Janssen's Tremfya — an IL-23/P19 inhibitor — in people living with moderate to severe plaque psoriasis, with a Psoriasis Area Severity Index, or PASI, 100 score as the primary endpoint.
Taltz showed superiority to Tremfya in the proportion of patients achieving complete skin clearance, according to Lilly.
The company said Taltz also met all major secondary endpoints up to week 12.
Why It's Important
Dermatologists aim for complete clear skin and rapid symptom relief.
The head-to-head data provides information for individual treatment goal discussions between health care providers and their patients, Andrew Blauvelt, M.D., a dermatologist and president of the Oregon Medical Research Center, said in a statement.
Lilly said it plans to submit detailed data from the study for presentations at future scientific meetings and peer-reviewed journals.
Lilly shares were up 1.6% at $115.47 at the time of publication Tuesday.
The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO
Axovant Analyst Turns Bullish Ahead Of Q4 Gene Therapy Data Readouts
See more from Benzinga
- Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates
- Biotech Stock On The Radar: Veru, A Catalyst-Rich Biopharma
- The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.